Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

CorMedix Inc. CRMD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
82/100
5/7 Pass
SharesGrow Intrinsic Value
$31.96
+342%
Analyst Price Target
$13.75
+90.2%

CorMedix Inc. (CRMD) is a Biotechnology company in the Healthcare sector, currently trading at $7.23. It has a SharesGrow Score of 82/100, indicating a strong investment profile with 5 out of 7 criteria passed.

SharesGrow calculates the intrinsic value of CRMD = $31.96 (+342% from the current price, the stock appears undervalued). Analyst consensus target is CRMD = $14 (+90.2% upside).

Valuation: CRMD trades at a trailing Price-to-Earnings (P/E) of 3.5 (S&P 500 average ~25).

Financials: revenue is $312M, +258.5%/yr average growth. Net income is $163M, growing at +338.2%/yr. Net profit margin is 52.3% (strong). Gross margin is 88.5% (-5.8 pp trend).

Balance sheet: total debt is $149M against $405M equity (Debt-to-Equity (D/E) ratio 0.37, conservative). Current ratio is 2.01 (strong liquidity). Debt-to-assets is 18%. Total assets: $826M.

Analyst outlook: 6 / 6 analysts rate CRMD as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 49/100 (Partial), Future 100/100 (Pass), Income 100/100 (Pass).

$13.75
▲ 90.18% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for CorMedix Inc., the average price target is $13.75, with a high forecast of $16.00, and a low forecast of $13.00.
Highest Price Target
$16.00
Average Price Target
$13.75
Lowest Price Target
$13.00

CRMD SharesGrow Score Overview

82/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 49/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CRMD

✓
VALUE Pass
100/100
CRMD trades at a trailing Price-to-Earnings (P/E) of 3.5 (S&P 500 average ~25). Forward PEG -0.1 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $14, implying +93.6% from the current price $7. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
CRMD: +258.5%/yr revenue is, +338.2%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
CRMD: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet CRMD: Debt-to-Equity (D/E) ratio 0.37 (conservative), Current ratio is 2.01 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
49/100
CRMD: Gross margin is 88.5% (-5.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 49/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 6 / 6 analysts rate CRMD as buy (100%). Analyst consensus target is $14 (+93.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✓
INCOME Pass
100/100
CRMD: Net profit margin is 52.3%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.6-17.43
Volume1.06M
Avg Volume (30D)1.7M
Market Cap$571.53M
Beta (1Y)1.41
Share Statistics
EPS (TTM)2.25
Shares Outstanding$72.03M
IPO Date2010-05-13
Employees64
CEOJoseph Todisco
Financial Highlights & Ratios
Revenue (TTM)$311.71M
Gross Profit$275.75M
EBITDA$165.13M
Net Income$163.06M
Operating Income$150.14M
Total Cash$149.52M
Total Debt$148.91M
Net Debt$3.09M
Total Assets$826.14M
Price / Earnings (P/E)3.2
Price / Sales (P/S)1.83
Analyst Forecast
1Y Price Target$13.00
Target High$16.00
Target Low$13.00
Upside+79.8%
Rating ConsensusBuy
Analysts Covering6
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS21900C3088

Price Chart

Track all markets on TradingView
CRMD
CorMedix Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
5.60 52WK RANGE 17.43

People Also View

CELC
CELC
Celcuity Inc.
$123.47
+2.17%
 TVTX
TVTX
Travere Therapeutics, Inc.
$40.95
-2.80%
 TARS
TARS
Tarsus Pharmaceuticals, Inc.
$71.80
-2.72%
 ELVN
ELVN
Enliven Therapeutics, Inc.
$43.95
-2.01%
 NUVB
NUVB
Nuvation Bio Inc.
$4.82
-0.72%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.60
+0.49%
 PGEN
PGEN
Precigen, Inc.
$3.90
-2.01%
 ETON
ETON
Eton Pharmaceuticals, Inc.
$26.97
-0.55%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message